Printer Friendly

MBI SUED BY COMPETITOR OVER ORAL AGENT

 SAN DIEGO, July 1 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) today responded to an announcement that it has been sued by a competitor, IMARx Pharmaceutical Corp. in the United States District Court in Tucson, Ariz. In its lawsuit, IMARx accuses MBI of having misappropriated trade secrets and of having competed unfairly with respect to an oral agent for gastrointestinal ultrasound.
 This lawsuit and a related interference proceeding in the U.S. Patent and Trademark Office are not related in any way to Albunex(R), MBI's pioneering ultrasound cardiac contrast agent, which is in the final stages of the FDA approval process, nor any other products which MBI is developing. MBI's oral agent is still in the preclinical stage.
 The claims in this matter relate to when MBI first announced in March 1991 that it was developing a new proprietary oral ultrasound gastrointestinal contrast agent. This lawsuit was not filed, however, until June 1993. IMARx has offered no explanation for the delay. IMARx does claim in its complaint that MBI's program has resulted in a "significant diminution in the value" of IMARx's own recent license for the competing technology.
 MBI intends to defend the lawsuit vigorously. MBI products are the work of its own proven research and development program, and not attributable to IMARx. The company has retained the firms of Morrison & Foerster of San Francisco and Streich Lang of Tucson to represent it in the litigation and interference actions.
 -0- 7/1/93
 /CONTACT: Sherry Mesman, VP-Finance & CFO, or Beth Field Wallace, investor relations, of Molecular Biosystems, 619-452-7393, ext. 2212/
 (MB)


CO: Molecular Biosystems Inc. ST: California IN: MTC SU:

JL-EH -- SD007 -- 7893 07/01/93 16:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1993
Words:280
Previous Article:FUND AMERICA INVESTORS CORP. II $75 MILLION SERIES 1993-B 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:SIEMENS ULTRASOUND BREAKS GROUND FOR NEW FACILITY IN ISSAQUAH, WASH.
Topics:


Related Articles
MOLECULAR BIOSYSTEMS INC. AND SYNGENE INC. COMMENT ON GEN-PROBE PATENT SUIT
MOLECULAR BIOSYSTEMS, DIRECTORS AND OFFICERS NAMED IN CLASS ACTION SUIT
MOLECULAR BIOSYSTEMS INC. SUBMITS PMA AMENDMENT TO FDA
MBI ANNOUNCES ALBUNEX(R) APPROVAL IN JAPAN
Molecular Biosystems and Mallinckrodt Report Final European Approval of OPTISON(TM)
Mallinckrodt and Molecular Biosystems Launch OPTISON in Europe
DuPont Pharmaceuticals and ImaRx Pharmaceutical Corp. File Patent Infringement Lawsuit Against Molecular Biosystems, Inc. and Mallinckrodt, Inc.
SONUS Pharmaceuticals Announces Settlement of Patent Infringement Lawsuit.
Molecular Biosystems, Mallinckrodt Announce Restructuring of OPTISON(R) Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters